Hiển thị các bài đăng có nhãn Eli Lilly. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn Eli Lilly. Hiển thị tất cả bài đăng
Thứ Hai, 14 tháng 4, 2014

Planned Obsolescence Disguised as Innovation, Oligopoly Disguised as a Free Market, and the Enrichment of Oligarchs

›
The New York Times published another article in its series on the high cost of US health care.  This one, focused on the care of type 1 di...
Thứ Năm, 13 tháng 3, 2014

As the Door Turns - The Ongoing Interchange of Leaders Among Large Health Care Corporations, Those who Represent Them, and Government

›
The revolving door is the two-way conduit between leadership positions in government and industry that helps to enable health care, and mayb...
Thứ Tư, 26 tháng 12, 2012

'Tis the Season for Legal Settlements: GlaxoSmithKline, Eli Lilly, Orthofix, Sanofi all Settle

›
Reports of legal settlements by big health care organizations tend to dribble out towards the end of the year, maybe in a rush to finalize t...
Thứ Ba, 18 tháng 1, 2011

"I'm Not Here to Sell Drugs" - Then Why Use Company Provided "Correct" Slides?

›
In October, 2010, we discussed a series of reports by Pro Publica and multiple other respected news organizations about payments by seven p...
Thứ Tư, 14 tháng 7, 2010

Eli Lilly CEO on “America’s Growing Innovation Gap”

›
In “ America’s Growing Innovation Gap ”, WSJ, July 9, 2010, Eli Lilly CEO John C. Lechleiter, Ph.D. writes that: “…the most important...
Thứ Hai, 10 tháng 5, 2010

Leaders of Discredited Financial Rating Agencies as Leaders of Health Care

›
This is the latest in our informal series on the cross-linkages between the thinking and leadership that lead to the global financial collap...
Thứ Tư, 17 tháng 2, 2010

Quintiles to More Heavily Directly Invest in the Drugs Which it Evaluates - But Not to Worry, Says an Expert?

›
The Associated Press just reported on the latest trend in commercially sponsored clinical research, direct investment by contract research o...
Thứ Ba, 16 tháng 6, 2009

Pharmacy Benefit Managers as Pharmaceutical Marketers

›
We posted a number of times about questionable practices Eli Lilly used to market its atypical anti-psychotic drug Zyprexa ( olanzapine ). ...